A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
Clinical trial NCT06340958 · COMPLETED
Trial details
- NCT number
- NCT06340958
- Sponsor
- Clexio Biosciences Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-18
- Primary completion
- 2025-06-06
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.